C50.A2: Malignant inflammatory neoplasm of left breast
C50.A2, malignant inflammatory neoplasm of left breast, is listed as a covered diagnosis in 12 Medicare billing and coding articles that apply to 89 HCPCS Level II codes, including J9217 (Leuprolide acetate (for depot suspension), 7.5 mg), J1952 (Leuprolide injectable, camcevi, 1 mg), J3315 (Injection, triptorelin pamoate, 3.75 mg). 10 of these codes have a 2026 DMEPOS fee schedule amount; L8035 pays $4,403.11 to $5,283.69 depending on the state. The articles come from 3 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.
HCPCS Level II codes with C50.A2 as a covered diagnosis
| Code | Description | Medicare coverage | DMEPOS fee 2026 (state range) | Articles listing it |
|---|---|---|---|---|
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Special coverage instructions apply | — | 2 |
| J1952 | Leuprolide injectable, camcevi, 1 mg | Carrier judgment | — | 2 |
| J3315 | Injection, triptorelin pamoate, 3.75 mg | Special coverage instructions apply | — | 2 |
| J1954 | Injection, leuprolide acetate for depot suspension (lutrate depot), 7.5 mg | Carrier judgment | — | 2 |
| J9202 | Goserelin acetate implant, per 3.6 mg | Special coverage instructions apply | — | 2 |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | Special coverage instructions apply | — | 2 |
| J9219 | Leuprolide acetate implant, 65 mg | Special coverage instructions apply | — | 2 |
| J9225 | Histrelin implant (vantas), 50 mg | Special coverage instructions apply | — | 2 |
| L8035 | Custom breast prosthesis, post mastectomy, molded to patient model, any type | Special coverage instructions apply | $4,403.11–$5,283.69 | 1 |
| L8002 | Breast prosthesis, mastectomy bra, with integrated breast prosthesis form, bilateral, any size, any type | Special coverage instructions apply | $198.27–$218.12 | 1 |
| L8001 | Breast prosthesis, mastectomy bra, with integrated breast prosthesis form, unilateral, any size, any type | Special coverage instructions apply | $150.77–$165.83 | 1 |
| L8015 | External breast prosthesis garment, with mastectomy form, post mastectomy | Special coverage instructions apply | $72.05–$86.41 | 1 |
| L8000 | Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type | Special coverage instructions apply | $44.70–$78.16 | 1 |
| A4280 | Adhesive skin support attachment for use with external breast prosthesis, each | Carrier judgment | $7.38–$8.13 | 1 |
| C9726 | Placement and removal (if performed) of applicator into breast for intraoperative radiation therapy, add-on to primary breast procedure | Special coverage instructions apply | — | 1 |
| J3316 | Injection, triptorelin, extended-release, 3.75 mg | Special coverage instructions apply | — | 1 |
| J9218 | Leuprolide acetate, per 1 mg | Special coverage instructions apply | — | 1 |
| Q0512 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period | Special coverage instructions apply | — | 2 |
| Q0511 | Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period | Special coverage instructions apply | — | 2 |
| J0897 | Injection, denosumab, 1 mg | Carrier judgment | — | 1 |
| Q5136 | Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg | Carrier judgment | — | 1 |
| Q5157 | Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg | Carrier judgment | — | 1 |
| Q5158 | Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg | Carrier judgment | — | 1 |
| Q5159 | Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg | Carrier judgment | — | 1 |
| Q5162 | Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg | Carrier judgment | — | 1 |
64 more codes are listed. See every code with payment by region in Caduvo.
Medicare policy articles listing C50.A2
- A52478: External Breast Prostheses - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC); 6 Level II codes). LCD with the same title: L33317
- A56684: Billing and Coding: Intraoperative Radiation Therapy (Palmetto GBA (MAC - Part A, MAC - Part B); 1 Level II codes). LCD with the same title: L37779
- A59160: Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (Palmetto GBA (MAC - Part A, MAC - Part B); 8 Level II codes). LCD with the same title: L39387
- A52453: Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (Wellpoint Federal (MAC - Part A, MAC - Part B); 10 Level II codes). LCD with the same title: L39387
- A52399: Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B); 10 Level II codes)
- A52370: Billing and Coding: Bevacizumab and biosimilars (Wellpoint Federal (MAC - Part A, MAC - Part B); 8 Level II codes)
- A52450: Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™) (Wellpoint Federal (MAC - Part A, MAC - Part B); 2 Level II codes)
- A59350: Billing and Coding: Radiation Therapies (Palmetto GBA (MAC - Part A, MAC - Part B); 2 Level II codes). LCD with the same title: L39553
- A52479: Oral Anticancer Drugs - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC); 8 Level II codes). LCD with the same title: L33826
- A56748: Billing and Coding: White Cell Colony Stimulating Factors (Palmetto GBA (MAC - Part A, MAC - Part B); 16 Level II codes). LCD with the same title: L37176
- A52480: Oral Antiemetic Drugs (Replacement for Intravenous Antiemetics) - Policy Article (CGS Administrators, LLC (DME MAC) Noridian Healthcare Solutions, LLC (DME MAC); 19 Level II codes). LCD with the same title: L33827
- A56695: Billing and Coding: Implantable Infusion Pump (Palmetto GBA (MAC - Part B); 9 Level II codes). LCD with the same title: L33461
A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.
Other C50 diagnoses (Malignant neoplasm of breast)
- C50.A0 — Malignant inflammatory neoplasm of unspecified breast
- C50.A1 — Malignant inflammatory neoplasm of right breast
- C50.011 — Malignant neoplasm of nipple and areola, right female breast
- C50.012 — Malignant neoplasm of nipple and areola, left female breast
- C50.019 — Malignant neoplasm of nipple and areola, unspecified female breast
- C50.021 — Malignant neoplasm of nipple and areola, right male breast
- C50.022 — Malignant neoplasm of nipple and areola, left male breast
- C50.029 — Malignant neoplasm of nipple and areola, unspecified male breast
- C50.111 — Malignant neoplasm of central portion of right female breast
- C50.112 — Malignant neoplasm of central portion of left female breast
- C50.119 — Malignant neoplasm of central portion of unspecified female breast
- C50.121 — Malignant neoplasm of central portion of right male breast
- C50.122 — Malignant neoplasm of central portion of left male breast
- C50.129 — Malignant neoplasm of central portion of unspecified male breast
- C50.211 — Malignant neoplasm of upper-inner quadrant of right female breast
- C50.212 — Malignant neoplasm of upper-inner quadrant of left female breast
- C50.219 — Malignant neoplasm of upper-inner quadrant of unspecified female…
- C50.221 — Malignant neoplasm of upper-inner quadrant of right male breast
- C50.222 — Malignant neoplasm of upper-inner quadrant of left male breast
- C50.229 — Malignant neoplasm of upper-inner quadrant of unspecified male breast
- C50.311 — Malignant neoplasm of lower-inner quadrant of right female breast
- C50.312 — Malignant neoplasm of lower-inner quadrant of left female breast
- C50.319 — Malignant neoplasm of lower-inner quadrant of unspecified female…
- C50.321 — Malignant neoplasm of lower-inner quadrant of right male breast
- C50.322 — Malignant neoplasm of lower-inner quadrant of left male breast
- C50.329 — Malignant neoplasm of lower-inner quadrant of unspecified male breast
- C50.411 — Malignant neoplasm of upper-outer quadrant of right female breast
- C50.412 — Malignant neoplasm of upper-outer quadrant of left female breast
- C50.419 — Malignant neoplasm of upper-outer quadrant of unspecified female…
- C50.421 — Malignant neoplasm of upper-outer quadrant of right male breast
Frequently asked questions
Does Medicare cover C50.A2 (Malignant inflammatory neoplasm of left breast)?
Medicare covers items and services, not diagnoses. 12 Medicare billing and coding articles list C50.A2 as a covered diagnosis for 89 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.
Which HCPCS codes can be billed with ICD-10 C50.A2?
The Level II codes from the policies most specific to this diagnosis are J9217 (Leuprolide acetate (for depot suspension), 7.5 mg, 2 articles); J1952 (Leuprolide injectable, camcevi, 1 mg, 2 articles); J3315 (Injection, triptorelin pamoate, 3.75 mg, 2 articles); J1954 (Injection, leuprolide acetate for depot suspension…, 2 articles); J9202 (Goserelin acetate implant, per 3.6 mg, 2 articles). Code choice depends on the item supplied; check each code's descriptor.
What does Medicare pay for equipment billed with C50.A2?
Under the 2026 DMEPOS fee schedule (non-rural state fees): L8035 $4,403.11 to $5,283.69; L8002 $198.27 to $218.12; L8001 $150.77 to $165.83; L8015 $72.05 to $86.41. Medicare pays 80% of the allowed amount after the Part B deductible.
Which Medicare policy articles list C50.A2?
A52478 (External Breast Prostheses - Policy Article); A56684 (Billing and Coding: Intraoperative Radiation Therapy); A59160 (Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs), and 9 more articles.
What is ICD-10-CM code C50.A2?
C50.A2 is the ICD-10-CM code for malignant inflammatory neoplasm of left breast, in category C50 (Malignant neoplasm of breast), chapter 2: Neoplasms.
Next steps
- Run a reimbursement report for a device billed under J9217
- Watch J9217 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9217
Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.